Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 284

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 284
---
 will be eligible to: (i) annual   
 compensation of $250, to be paid on a quarterly basis; (ii) a grant of 283,532 options with an exercise price of NIS 0.01; and (iii) 
 at Qualified IPO (as defined below), a cash payment of $500. In addition,the holdings of the chairman of the Company’s board of      
 directors shall not be diluted any lower than 9.98% as a result of any IPO with a total proceeds of no less than $6,000 (“Qualified  
 IPO”).                                                                                                                               |

| 3. | Increase of authorized share capital from 3,000,000 to 22,500,000 
 shares.                                                           |

| 4. | Cancellation of the                                                  
 Company’s nominal value per each Ordinary Share and preferred share. |

On March 31, 2025, the Company and
the lenders of certain short-term loan agreements and convertible notes, signed an amendment to extend the maturity date of the loans
(see Note 5c, 5d and Note 6).

In April 2025, the Company entered
into bridge loan agreements (the “April 2025 Loans” or "April 2025 Loan Agreements"), pursuant to which the Company
obtained bridge loans from the lenders thereto including certain related parties, including the Company's chairman of the board of directors,
a member of the Company's board of directors, and a director nominee. The April 2025 Loans shall bear interest at 8% per annum until
maturity and the Company agreed to pay the lenders an additional risk premium equal to 50% of their respective loan amount.

The April 2025 Loan's maturity date
is the earlier of August 31, 2025, or the date of consummation of the QIPO. Furthermore, upon the occurrence of a QIPO, the April 2025
Loan lenders, shall be granted warrants to purchase such number of Ordinary Shares equal to two times their respective loan amount in
addition to the risk premium based on a price per share equal to 75% of the lowest price per share of the Ordinary Shares during the
first five trading days following the consummation of such IPO.

<div align='center'>F-30

1,000,000 Ordinary Shares

Regentis Biomaterials Ltd.</div>

| PRELIMINARY PROSPECTUS |

<div align='center'>ThinkEquity

,